Next Article in Journal
Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2
Next Article in Special Issue
Longitudinal Assessment of BNT162b2- and mRNA-1273-Induced Anti-SARS-CoV-2 Spike IgG Levels and Avidity Following Three Doses of Vaccination
Previous Article in Journal
Human Papillomavirus Vaccination Acceleration and Introduction in Sub-Saharan Africa: A Multi-Country Cohort Analysis
Previous Article in Special Issue
Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins
 
 
Article

Article Versions Notes

Vaccines 2024, 12(5), 491; https://doi.org/10.3390/vaccines12050491
Action Date Notes Link
article pdf uploaded. 1 May 2024 18:07 CEST Version of Record https://www.mdpi.com/2076-393X/12/5/491/pdf-vor
article xml file uploaded 9 May 2024 08:34 CEST Original file -
article xml uploaded. 9 May 2024 08:34 CEST Update https://www.mdpi.com/2076-393X/12/5/491/xml
article pdf uploaded. 9 May 2024 08:34 CEST Updated version of record https://www.mdpi.com/2076-393X/12/5/491/pdf
article supplementary file uploaded. 9 May 2024 08:34 CEST - https://www.mdpi.com/2076-393X/12/5/491#supplementary
article html file updated 9 May 2024 08:38 CEST Original file https://www.mdpi.com/2076-393X/12/5/491/html
Back to TopTop